Gonadotropin Salgılayan Hormon Antagonistleri
Özet
Androjen deprivasyon tedavisi (ADT), metastatik veya yüksek riskli lokalize prostat kanseri tedavisinin temelini oluşturmaktadır. Bu tedavinin temel amacı, serum testosteron düzeyini kastrasyon seviyesine düşürerek kanser hücrelerinin büyümesini engellemektir. Geleneksel olarak kullanılan LHRH agonistleri, tedavinin başlangıcında testosteron seviyelerinde geçici bir artışa (alevlenme fenomeni) yol açarken, yeni nesil Gonadotropin Salgılayan Hormon (GnRH) antagonistleri bu olumsuz duruma neden olmadan testosteronu doğrudan ve hızla baskılar. Üçüncü kuşak subkutan bir antagonist olan degarelix ve ilk oral GnRH antagonisti olan relugolix, bu gruptaki öne çıkan ajanlardır. Yapılan faz çalışmaları ve meta-analizler, GnRH antagonistlerinin LHRH agonistlerine kıyasla testosteron seviyelerini daha hızlı düşürdüğünü, alt üriner sistem semptomlarında belirgin bir iyileşme sağladığını ve PSA progresyonsuz sağkalım süresini uzattığını göstermiştir. Enjeksiyon bölgesi reaksiyonları antagonistlerde daha sık görülse de, bu ilaçların kas-iskelet sistemi ve özellikle kardiyovasküler yan etkiler açısından daha güvenli bir profile sahip olduğu saptanmıştır. Bu nedenle GnRH antagonistleri, özellikle eşlik eden kardiyovasküler komorbiditesi bulunan ileri evre prostat kanseri hastalarında klinik olarak daha güvenilir ve etkili bir tedavi seçeneği sunmaktadır.
Androgen deprivation therapy (ADT) serves as the cornerstone in managing metastatic or high-risk localized prostate cancer. The primary goal of ADT is to suppress serum testosterone to castration levels, thereby preventing the proliferation of androgen-dependent cancer cells. While traditional LHRH agonists induce a transient testosterone surge known as the flare phenomenon, gonadotropin-releasing hormone (GnRH) antagonists directly and rapidly inhibit gonadotropin production without causing this initial spike. Degarelix, a third-generation subcutaneous injection, and relugolix, the first approved oral GnRH antagonist, represent key advancements in this therapeutic class. Phase III clinical trials and subsequent meta-analyses demonstrate that GnRH antagonists achieve rapid testosterone suppression within days, significantly improve lower urinary tract symptoms, and extend prostate-specific antigen (PSA) progression-free survival compared to standard agonists. Although GnRH antagonists are associated with higher rates of local injection site reactions, they exhibit a superior safety profile regarding musculoskeletal issues and major adverse cardiovascular events. Consequently, GnRH antagonists constitute a highly effective and safer therapeutic alternative, particularly for advanced prostate cancer patients with pre-existing cardiovascular comorbidities.
Referanslar
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232-240. doi:10.3322/canjclin.22.4.232
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43(2):209–223.
Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0
Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1(Suppl 1):S3-S8.
Dellis A, Papatsoris A. Therapeutic outcomes of the LHRH antagonists. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):481-488. doi:10.1080/14737167.2017.1375855
Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011;29(27):3651-3658. doi:10.1200/JCO.2011.35.2005
Kolinsky M, de Bono JS. The Ongoing Challenges of Targeting the Androgen Receptor. Eur Urol. 2016;69(5):841-843. doi:10.1016/j.eururo.2015.10.052
McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58(5):756-761. doi:10.1016/s0090-4295(01)01342-5
Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009;69(14):1967-1976. doi:10.2165/10484080-000000000-00000
Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002;301(1):95-102. doi:10.1124/jpet.301.1.95
Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3(3):127-140. doi:10.1177/1756287211414457
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. doi:10.1111/j.1464-410X.2008.08183.x
Klotz L. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. Expert Opin Drug Metab Toxicol. 2015;11(11):1795-1802. doi:10.1517/17425255.2015.1085506
Sonesson A, Rasmussen BB. In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker. Drug Metab Dispos. 2013;41(7):1339-1346. doi:10.1124/dmd.113.051706
Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57(5):836-842. doi:10.1016/j.eururo.2009.11.029
Crawford ED, Shore ND, Moul JW, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014;83(5):1122-1128. doi:10.1016/j.urology.2014.01.013
Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66(6):1101-1108. doi:10.1016/j.eururo.2013.12.063
Sciarra A, Fasulo A, Ciardi A, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer [published correction appears in Medicine (Baltimore). 2016 Dec 09;95(49):e5671]. Medicine (Baltimore). 2016;95(27):e3845. doi:10.1097/MD.0000000000003845
Abufaraj M, Iwata T, Kimura S, et al. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Eur Urol. 2021;79(1):44-53. doi:10.1016/j.eururo.2020.06.002
Schröder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010;106(2):182-187. doi:10.1111/j.1464-410X.2009.08981.x
Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90(3):321-328. doi:10.1159/000345423
Mason M, Richaud P, Bosnyak Z, Malmberg A, Neijber A. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis. Low Urin Tract Symptoms. 2017;9(2):82-88. doi:10.1111/luts.12114
Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013;25(3):190-196. doi:10.1016/j.clon.2012.09.010
MacLean DB, Shi H, Faessel HM, Saad F. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. J Clin Endocrinol Metab. 2015;100(12):4579-4587. doi:10.1210/jc.2015-2770
Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. Eur Urol. 2020;78(2):184-192. doi:10.1016/j.eururo.2020.03.001
Saad F, Bailen JL, Pieczonka CM, et al. Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). J Clin Oncol. 2016;34:200
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Front Oncol. 2018;8:543. Published 2018 Nov 27. doi:10.3389/fonc.2018.00543
Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565-573. doi:10.1016/j.eururo.2013.10.032
Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men. Clin Drug Investig. 2017;37(9):873-879. doi:10.1007/s40261-017-0547-7.
Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial [published correction appears in Circulation. 2021 Oct 19;144(16):e273]. Circulation. 2021;144(16):1295-1307. doi:10.1161/CIRCULATIONAHA.121.056810
Zengerling F, Jakob JJ, Schmidt S, et al. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021;8(8):CD012548. Published 2021 Aug 5. doi:10.1002/14651858.CD012548.pub2
Sawazaki H, Araki D, Kitamura Y, Yagi K. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study. World J Urol. 2020;38(6):1465-1471. doi:10.1007/s00345-019-02937-x
Tokiwa S, Shimmura H, Nomura S, et al. Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. Res Rep Urol. 2017;9:225-232. Published 2017 Dec 6. doi:10.2147/RRU.S146180
Mohamad NV, Ima-Nirwana S, Chin KY. The Skeletal Effects of Gonadotropin-Releasing Hormone Antagonists: A Concise Review. Endocr Metab Immune Disord Drug Targets. 2021;21(10):1713-1720.
Jayusman PA, Mohamed IN, Shuid AN. The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats. Int J Endocrinol Metab. 2018;16(3):e64038. Published 2018 Jul 2. doi:10.5812/ijem.64038
